EGFR and non-small cell lung carcinoma: We included eight RCTs, one Non‐RCT, and eight retrospective studies involving 2085 NSCLC patients with EGFR mutations who progressed prior treatment with EGFR‐TKI and received ICIs alone or in combination with follow‐up therapy.